Avadel Pharmaceuticals plc (AVDL)

Market Cap	1.23B
Revenue (ttm)	221.08M
Net Income (ttm)	-2.92M
Shares Out	96.90M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	29.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,983,687
Open	14.00
Previous Close	11.10
Day's Range	11.63 - 14.23
52-Week Range	6.38 - 17.30
Beta	1.63
Analysts	Strong Buy
Price Target	19.00 (+49.14%)
Earnings Date	Aug 7, 2025

About AGR

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 7, 1996
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: AVDL
• Website: https://www.avadel.com

Financial Performance

In 2024, Avadel Pharmaceuticals's revenue was $169.12 million, an increase of 504.79% compared to the previous year's $27.96 million. Losses were -$48.83 million, -69.53% less than in 2023.

Analyst Summary

According to 7 analysts, the average rating for AVDL stock is "Strong Buy." The 12-month stock price target is $19.0, which is an increase of 49.14% from the latest price.

Price Target

$19.0

(49.14% upside)

Analyst Consensus: Strong Buy